Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Exousia Bio (LMMY) EBITDA (2022 - 2025)

Lamy (LMMY) has disclosed EBITDA for 4 consecutive years, with -$237005.0 as the latest value for Q4 2025.

  • Quarterly EBITDA fell 3495.0% to -$237005.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$279402.0 through Nov 2025, down 3403.01% year-over-year, with the annual reading at -$17465.0 for FY2025, 0.0% changed from the prior year.
  • EBITDA hit -$237005.0 in Q4 2025 for Lamy, down from -$31814.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $17601.0 in Q2 2023 to a low of -$237005.0 in Q4 2025.
  • Historically, EBITDA has averaged -$21788.2 across 4 years, with a median of -$8338.0 in 2022.
  • Biggest five-year swings in EBITDA: skyrocketed 193.73% in 2024 and later tumbled 4676.88% in 2025.
  • Year by year, EBITDA stood at -$8407.0 in 2022, then grew by 11.41% to -$7448.0 in 2023, then skyrocketed by 193.73% to $6981.0 in 2024, then tumbled by 3495.0% to -$237005.0 in 2025.
  • Business Quant data shows EBITDA for LMMY at -$237005.0 in Q4 2025, -$31814.0 in Q3 2025, and -$16748.0 in Q2 2025.